Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


Published online before print August 15, 2007, doi:10.1212/01.wnl.0000277638.63767.b8)
This Article
Right arrow Full Text (Rapid PDF)
Right arrow All Versions of this Article:
01.wnl.0000277638.63767.b8v1
69/15/1542    most recent
Right arrow Correspondence:
Submit a response
Right arrow Correspondence:
View responses
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Inzelberg, R.
Right arrow Articles by Jankovic, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Inzelberg, R.
Right arrow Articles by Jankovic, J.
Received November 27, 2006
Accepted February 27, 2007

Are Parkinson disease patients protected from some but not all cancers?

Rivka Inzelberg MD* and Joseph Jankovic MD

From the Department of Neurology (R.I.), Meir Hospital, Kfar Saba, and Rappaport Faculty of Medicine (R.I.), Technion, Haifa, Israel; and Department of Neurology (J.J.), Baylor College of Medicine, Houston, TX.


* To whom correspondence should be addressed. E-mail: rivka.inzelberg{at}clalit.org.il.

ABSTRACT

There is substantial evidence based on well designed epidemiologic studies for low cancer rates in patients with Parkinson disease (PD). This risk reduction cannot be attributed to the recognized low life-long incidence of smoking in patients with PD, as not only smoking-related cancers but also non-smoking-related ones are less common in PD. Whereas the risk for most cancers appears to be relatively low in patients with PD, breast cancer and melanomas occur more frequently in the PD population as compared with controls. The relationship between this peculiar pattern of cancer rates and PD might be related to the involvement of common genes in both diseases. Mutations in parkin gene, for example, have been reported in several types of cancer. Furthermore, genes involved in familial forms of PD appear to be abnormally expressed in cancers. Thus, parkin and PINK1 might be tumor suppressor genes, whereas DJ-1 is an oncogene. Cell survival signals may differ owing to mutated genes and represent two opposite extremes such as cell proliferation in cancer and cell death due to apoptosis in PD. Unraveling the link between PD and cancer may open a therapeutic window for both diseases.




This article has been cited by other articles:


Home page
J. Neurol. Neurosurg. PsychiatryHome page
J Jankovic
Parkinson's disease: clinical features and diagnosis
J. Neurol. Neurosurg. Psychiatry, April 1, 2008; 79(4): 368 - 376.
[Abstract] [Full Text] [PDF]

Correspondence:

Read all Correspondence

Are Parkinson disease patients protected from some but not all cancers?
Audrey J. Strongosky, et al.
Neurology Online, 25 Feb 2008 [Full text]
Reply from the authors
Rivka Inzelberg, et al.
Neurology Online, 25 Feb 2008 [Full text]



HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2007 by AAN Enterprises, Inc.